Análise de eficácia de acordo com valores de TMB no CheckMate 9LA
Por um escritor misterioso
Descrição
O tumor mutation burden (TMB) está potencialmente associado à eficácia clínica dos inibidores de correceptores imunes. Durante o ELCC 2022, foram apresentados os dados de eficácia da combinação de nivolumabe + ipilimumabe + quimioterapia segundo os valores de TMB tanto do tecido tumoral quanto do sangue dos pacientes.
ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in Patients With Tumor PD-L1<1% With 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone for mNSCLC
PDF) The efficacy of immune checkpoint inhibitors in thoracic malignancies
PDF) TERAPIA FOTODINÂMICA ATIVADA POR RAIOS X POR INTERMÉDIO DE NANOPARTÍCULAS CINTILADORAS: REVISÃO INTEGRATIVA, Revista Portuguesa de Oncologia
PDF) Perspectivas da imunoterapia em pacientes com câncer de pulmão metastático
Identification and functional annotation of risk score-related genes. A
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - ScienceDirect
Arquivo de GBCP - GBCP
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial - The Lancet
Oncologia Clínica: Curso Preparatório para Prova de Título de Especialista em, PDF, Câncer
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA
PDF) Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - ScienceDirect
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - ScienceDirect
Ana Moreno (@superanitamix) / X
de
por adulto (o preço varia de acordo com o tamanho do grupo)
